Literature DB >> 22497305

Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome.

So-Jung Liang1, Tsan-Hon Liou, Hui-Wen Lin, Chun-Sen Hsu, Chii-Ruey Tzeng, Ming-I Hsu.   

Abstract

OBJECTIVE: To evaluate the contribution to glucose intolerance and metabolic syndrome of obesity combined with the diagnostic criteria of polycystic ovary syndrome (PCOS).
DESIGN: Prospective study.
SETTING: University teaching hospital from 31 August 2010 to 31 August 2011. POPULATION: Two hundred and twenty women with PCOS and seventy normal control women.
METHODS: The clinical and biochemical characteristics of women with PCOS and control women were evaluated. Main outcome measures. The impact of obesity, hyperandrogenism, oligo-anovulation and polycystic ovary morphology on impaired glucose tolerance and metabolic disturbances.
RESULTS: Obese women with PCOS had significantly higher insulin resistance than obese normal control women. Logistic regression analysis showed that obesity was the only factor that predicted impaired glucose tolerance and metabolic syndrome. Use of the area under the receiver operating characteristic curve (AUROC) for the body mass index to predict impaired glucose tolerance and metabolic syndrome was more accurate than AUROCs for serum total testosterone level and the average menstrual interval.
CONCLUSIONS: Body weight status was the major factor determining the risk of impaired glucose tolerance and metabolic syndrome in women with PCOS. Obesity should be treated as the major factor determining long-term health consequences associated with PCOS.
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22497305     DOI: 10.1111/j.1600-0412.2012.01417.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  Low Serum 25-Hydroxyvitamin D Levels Are Associated With Hyperandrogenemia in Polycystic Ovary Syndrome: A Cross-Sectional Study.

Authors:  Chang Shan; Yu-Chen Zhu; Jie Yu; Yi Zhang; Yu-Ying Wang; Nan Lu; Jie Cai; Wei Liu; Tao Tao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-02       Impact factor: 6.055

2.  Characterization of polycystic ovary syndrome among Flo app users around the world.

Authors:  Tarun Jain; Olivia Negris; Dannielle Brown; Isabel Galic; Rodion Salimgaraev; Liudmila Zhaunova
Journal:  Reprod Biol Endocrinol       Date:  2021-03-03       Impact factor: 5.211

Review 3.  Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome.

Authors:  Haigang Ding; Juan Zhang; Feng Zhang; Songou Zhang; Xiaozhen Chen; Wenqing Liang; Qiong Xie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-20       Impact factor: 5.555

4.  Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Chenchen Zhuang; Xufei Luo; Wenjuan Wang; Runmin Sun; Miaomiao Qi; Jing Yu
Journal:  Front Cardiovasc Med       Date:  2022-02-16

5.  Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study.

Authors:  Chun Yuan; Xiaoqiang Liu; Yundong Mao; Feiyang Diao; Yugui Cui; Jiayin Liu
Journal:  J Biomed Res       Date:  2016-04-30

6.  Association between melatonin receptor gene polymorphisms and polycystic ovarian syndrome: a systematic review and meta-analysis.

Authors:  Shiqi Yi; Jiawei Xu; Hao Shi; Wenbo Li; Qian Li; Ying-Pu Sun
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.